Tenax Therapeutics, Inc. filed a current report on Form 8-K on August 10, 2026, announcing topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF, along with a conference call and live webcast held the same day.

Key Highlights

  • Trial results announced: Tenax Therapeutics disclosed topline results from its Phase 3 LEVEL clinical trial of TNX-103 in patients with PH-HFpEF.
  • Conference call scheduled: The company hosted a conference call and live webcast at 8:00 a.m. ET on August 10, 2026 related to the trial results.
  • Supporting materials filed: A press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2), both dated August 10, 2026, were attached to the filing.
  • Signed by CEO: The report was signed by Christopher T. Giordano, President and Chief Executive Officer.
  • Exchange listing: Tenax Therapeutics common stock, $0.0001 par value per share, trades on The Nasdaq Stock Market LLC under the symbol TENX.

Tenax Therapeutics Discloses Phase 3 LEVEL Trial Data for TNX-103 in PH-HFpEF

Tenax Therapeutics, Inc. (NASDAQ: TENX), a biopharmaceutical company headquartered at 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, filed a current report on August 10, 2026, under Item 8.01 (Other Events) of the Securities Exchange Act of 1934. According to the filing, the company issued a press release on that date announcing topline results from its Phase 3 LEVEL clinical trial evaluating TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, referred to in the filing as PH-HFpEF.

The filing states that the company hosted a conference call and live webcast at 8:00 a.m. ET on August 10, 2026, in connection with those results. The filing does not detail the specific trial outcomes within the body of the 8-K itself; the substantive results are contained in the attached press release (Exhibit 99.1) and an investor presentation the company indicated it intended to display during the live webcast (Exhibit 99.2), both dated August 10, 2026.

The report was signed on August 10, 2026, by Christopher T. Giordano in his capacity as President and Chief Executive Officer of Tenax Therapeutics, Inc. The company is incorporated in Delaware and carries Commission File Number 001-34600.

What Was Disclosed

Tenax Therapeutics filed an 8-K on August 10, 2026, reporting that topline results from the Phase 3 LEVEL clinical trial of TNX-103 in PH-HFpEF patients were issued via press release, with supporting materials attached as exhibits to the filing.